US Broker Ratings

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Unpacking the 37.86% Potential Upside

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a biopharmaceutical company headquartered in Boulder, Colorado, has captured investor attention with a compelling potential upside of 37.86%. This promising figure, combined with a robust..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring a Potential 167.64% Upside

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical endeavor that stands at the forefront of developing treatments for rare and ultra-rare genetic diseases. This California-based company, with a market capitalization..

GeneDx Holdings Corp. (WGS) Investor Outlook: A 117% Potential Upside Sparks Interest

GeneDx Holdings Corp. (NASDAQ: WGS), a prominent player in the healthcare sector, specifically within the diagnostics and research industry, is capturing investor attention with its remarkable potential upside. With a..

Bausch Health Companies Inc. (BHC) Stock Analysis: Exploring a Potential 51% Upside

Bausch Health Companies Inc. (NYSE: BHC), a diversified healthcare entity, has drawn attention from investors with its impressive potential upside of 51.26%, as indicated by the current analyst target price..

Biohaven Ltd. (BHVN) Stock Analysis: Unpacking a 154% Potential Upside in Biotech

Biohaven Ltd. (BHVN), a prominent player in the biotechnology sector, has been capturing investor attention due to its promising pipeline of therapeutics and an impressive potential upside. Headquartered in New..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Biotech with 14% Upside Potential

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) stands out in the biotechnology sector, not only for its innovative pipeline but also for its promising potential upside. With a market capitalization of $6.29..

Beam Therapeutics Inc. (BEAM) Stock Analysis: Exploring a 98% Upside Potential in the Biotech Sector

Beam Therapeutics Inc. (NASDAQ: BEAM), a pioneering entity in the biotechnology sector, has emerged as a promising contender in the healthcare industry. With a market capitalization of $2.56 billion, this..

Warby Parker Inc. (WRBY) Stock Analysis: Strong Buy Ratings Signal Potential 20% Upside

Warby Parker Inc. (NYSE: WRBY), a prominent player in the eyewear industry, has captured the attention of investors with its innovative business model and robust growth prospects. At the forefront..

BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Analyzing a Promising 117% Upside Potential

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) stands out in the healthcare sector, particularly within the drug manufacturing space, for its robust pipeline and substantial growth potential. With a market capitalization of..

NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 63.41% Upside with Promising Biotech Innovations

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is making waves in the biotechnology sector with its innovative approach to treating cardiometabolic diseases. With a market capitalization of $3.45 billion, this Netherlands-based..

Twist Bioscience Corporation (TWST) Stock Analysis: Insights into a 12% Potential Upside

Twist Bioscience Corporation (NASDAQ: TWST), a dynamic player in the healthcare sector specializing in diagnostics and research, is capturing the attention of investors with its promising growth trajectory and innovative..

Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Market Challenges with 23.7% Revenue Growth

Amicus Therapeutics, Inc. (NASDAQ: FOLD), a key player in the biotechnology sector, is making waves with its commitment to developing innovative treatments for rare diseases. Despite operating in a challenging..

ImmunityBio, Inc. (IBRX) Stock Analysis: A Biotech with 57% Upside Potential and Rapid Revenue Growth

ImmunityBio, Inc. (NASDAQ: IBRX) has captured investor attention with its remarkable positioning in the biotechnology sector. The San Diego-based company focuses on innovative immunotherapies aimed at activating the immune system..

Vericel Corporation (VCEL) Stock Analysis: Exploring a 70% Potential Upside in Biotech Investment

Vericel Corporation (NASDAQ: VCEL), a leading player in the healthcare sector, particularly within the biotechnology industry, has been catching the eye of investors with its robust growth metrics and promising..

Centessa Pharmaceuticals (CNTA) Stock Analysis: Exploring a 55% Upside Potential in Biotech

Centessa Pharmaceuticals plc (NASDAQ: CNTA) is capturing investor attention with its robust growth potential in the biotechnology sector. Based in Altrincham, United Kingdom, the company is making significant strides in..

BGM Group Ltd. (BGM) Stock Analysis: Navigating a Challenging Landscape with Strategic Insights

BGM Group Ltd. (BGM), a burgeoning entity in the healthcare sector, specifically within the specialty and generic drug manufacturing industry, presents a complex tapestry for investors. Incorporated in 2019 and..

Zai Lab Limited (ZLAB): Investor Outlook Highlights 118% Potential Upside

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the healthcare sector specializing in biotechnology, is garnering considerable attention from investors. Based in Pudong, China, Zai Lab focuses on the..

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: A 40% Upside Potential Beckons Investors

Amneal Pharmaceuticals, Inc. (AMRX), a key player in the healthcare sector, has emerged as a compelling opportunity for investors seeking exposure to the burgeoning field of drug manufacturing, specifically within..

Envista Holdings Corporation (NVST) Stock Analysis: Revenue Growth Shines Amid Mixed Valuation Metrics

Envista Holdings Corporation (NYSE: NVST) is an intriguing player in the healthcare sector, specifically within the medical instruments and supplies industry. Headquartered in Brea, California, Envista develops, manufactures, and markets..

CG Oncology, Inc. (CGON) Stock Analysis: High Potential Upside in the Biotech Sector

Investors in the biotechnology sector are keeping a close eye on CG Oncology, Inc. (NASDAQ: CGON) as it continues to make significant strides in the treatment of bladder cancer with..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds